MDxHealth SA announced the successful closing of its acquisition of the ExoDx business from Bio-Techne Corporation. This transaction includes the ExoDx Prostate test, a CLIA-certified clinical laboratory, and associated assets.
The definitive agreement for this acquisition was initially signed on August 5, 2025. The total consideration for the acquisition is $15 million, with $5 million paid in stock at closing and the remaining $10 million to be paid annually over the next four years, with 50% payable in cash and 50% in cash or stock at MDxHealth’s discretion.
This acquisition is expected to significantly strengthen MDxHealth's precision diagnostics portfolio, particularly its liquid-based diagnostic capabilities in prostate cancer. The ExoDx business is projected to contribute over $20 million in revenue in 2026 and accelerate the company's revenue growth rate to approximately 30% in 2026.
The integration of the ExoDx business is also anticipated to be accretive to MDxHealth's adjusted EBITDA starting in the fourth quarter of 2025. This strategic move enhances the company's market position and expands its offerings in the urology diagnostics market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.